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Background: Herpes zoster (HZ) is common among HIV-infected individuals, but the impacts of highly active
antiretroviral therapy (HAART) and HAART adherence on HZ risk have not been well studied.
Methods: The effects of HAART and HAART adherence on HZ incidence were evaluated by comparing HIV-infected
women on HAART (HAART use group) with the HIV-infected women remaining HAART naïve (HAART naïve group)
in the Women’s Interagency HIV Study (WIHS). A 1:1 matching with propensity score for predicting HAART initiation
was conducted to balance background covariates at index visit, including HIV disease stage. Kaplan-Meier method
was used to compare the risk of HZ development between the matched pairs. Cox proportional hazard models
were used to assess the effects of HAART and HAART adherence on HZ incidence.
Results: Through propensity score matching, 389 pairs of participants were identified and they contributed 3,909
person years after matching. The background covariates were similar between the matched pairs at the index visit.
The participants had a mean age around 39 years old, and about 61% of them were Black and 22% were Latina. No
significant difference in HZ risk was observed between the HAART use group and the HAART naïve group during
the first year of follow-up in any analyses. In the univariate analysis, the HAART use group had marginally lower HZ
risk (Hazard Ratio (HR): 0.72; 95% Confidence Interval (CI): 0.48-1.1) over the entire follow-up period. However,
women with a HAART adherence level of ≥95% had significantly lower HZ risk (HR: 0.54; 95% CI: 0.31, 0.94)
compared to the HAART naïve women. The association remained significant after adjusting for quality of life score
and acyclovir use, but it attenuated and was no longer statistically significant after adjusting for an intermediate
variable, either CD4+ T cell counts or HIV viral load.
Conclusions: Among adult women, we observed a significant preventive effect of long-term HAART use on HZ
incidence when a HAART adherence level of ≥95% was attained, and this effect was mediated through reduction
of HIV viral load and improvement of CD4+ T cell counts.
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Highly active antiretroviral therapy (HAART) has been
demonstrated to be very effective in decreasing the inci-
dence of opportunistic infections, acquired immunodefi-
ciency syndrome (AIDS) and death among HIV-infected
patients. However, previous studies showed that the inci-
dence of herpes zoster (HZ) is less likely than those of
other opportunistic infections to be reduced by HAART
as it still occurs at a relatively high rate in the HAART
era [1-3].
According to studies conducted so far, the effect of
HAART on HZ incidence may differ depending on how
long HAART has been used. Martinez et al. first re-
ported a high HZ incidence in patients with AIDS soon
after initiation of therapy with protease inhibitors [4].
Later, many other studies confirmed their observation as
part of an immune reconstitution inflammatory syndrome
[5-15]. It was proposed that this transient increase of HZ
risk may be associated with immunodysregulation rather
than profound immunesuppression. However, other stu-
dies showed no association of HZ incidence with recent
HAART initiation [2,16].
The long-term effect of HAART on HZ incidence has
also been inconsistent across studies. One study repor-
ted that the HZ incidence did not change between the
pre-HAART era and the HAART era, and that being on
HAART was associated with a high risk of HZ [16]. Fur-
thermore, there are anecdotal reports of failure of anti-
retroviral therapy to control HZ complications, such as
varicella zoster retinitis [17]. However, many other stu-
dies showed a protective effect of HAART on the in-
cidence of HZ [18-21] and its complications [16,22].
Unfortunately, most of these studies did not take into
account HAART adherence, which might partially ex-
plain the inconsistent results observed.
The objective of our study was to examine the effects
of HAART and HAART adherence on HZ incidence by
comparing HIV-infected women on HAART as a group
(HAART use group) or stratified by HAART adherence
level, with the matched HIV-infected HAART naive
women (HAART naïve group) using longitudinal data
from the Women’s Interagency HIV Study (WIHS).
Methods
Study population
The WIHS was initiated in 1993/1994 and expanded in
2001/2002 to examine the natural and treated history of
HIV disease among women. The study design of the
WIHS is detailed elsewhere [23,24]. Briefly, 2,813 HIV-
infected and 953 high risk HIV-negative women were re-
cruited from six study sites (Chicago, Los Angeles, San
Francisco, Washington D.C., Brooklyn and the Bronx) in
the United States. Women visit a study site every 6
months. During each visit, structured interviews areperformed to collect data on socio-demographical char-
acteristics, sexual behaviors, substance use, health care
utilization, antiretroviral therapy, treatments of comorbi-
dities and different disease outcomes. In addition, physical
and obstetric/gynecologic examinations are performed
and biological specimens are collected. The local institu-
tional review board at each site has approved the study
protocol, and all women have given their written informed
consents. For this study, our analyses were restricted to
the HIV-infected participants only.
Propensity score matching
Unlike in randomized clinical trials, use of therapy in
observational studies is not based upon random as-
signment. Thus, unbalanced distributions of background
covariates may bias estimated treatment effects. To ac-
count for this, a propensity score matching method was
used in our analysis. This method approaches more
closely a randomized clinical trial by balancing back-
ground covariates via matching propensity score, which
is the probability of HAART initiation in our study. The
propensity score was calculated for each subject at each
of her visits before starting HAART using a logistic re-
gression model, with potential confounders for HAART
initiation as predictors, including age, race, education,
AIDS status, CD4+ and CD8+ T cell counts, HIV viral
load and quality of life score. Each HAART user was
matched at the last visit before her HAART initiation to
a visit of a HAART naïve participant with similar pro-
pensity score (±0.1%). For any HAART naïve participant
already selected as a control, the rest of her visits were
removed from the matching pool to ensure 1:1 matching
ratio. Participants who had HZ history on or before the
matched visits were also removed from the analysis. The
matched visits are the index visits after which all follow-
up occurs in this analysis.
Study variables
We used a longitudinal cohort design to assess the im-
pact of HAART use and its adherence on HZ incidence.
In the WIHS, questions about HZ occurrence were asked
from visit 1 (October 1994) to visit 30 (April 2009). At
WIHS study enrollment, participants were asked “Has a
health care provider ever told you that you had shingles
(herpes zoster)?” At follow up visits, participants were
asked “Since your last visit, has a health care provider told
you that you had shingles (herpes zoster)?” The study out-
come was time to first HZ event from the index visit and
participants were censored at the last study visit, death, or
loss to follow up. As a participant usually had difficulty in
recalling exact date of a HZ event, we used a visit date as
the HZ event date when HZ was first reported at that visit,
in our calculation of time to first HZ event. The exposure
variables were HAART use group (yes/no) and HAART
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was guided by the DHHS/Kaiser Panel guidelines [25].
The HAART use group was defined as the matched
HAART using women, while the HAART naïve group
was defined as the matched women who never initiated
HAART during the follow-up. HAART adherence level
was self-reported and at each visit participants were asked
the extent to which they took antiretrovirals as prescribed
over the past 6 months. Participants categorized their level
of adherence into one of five categories: 100% of the time,
95-99% of the time, 75-94% of the time, <75% of the time,
and have not taken any prescribed medications. In WIHS,
a shortened version of MOS-HIV developed by Bozzette
et al. was adopted to measure QOL and its summary score
was used [26]. The score ranged from 0–100, with higher
score indicating better QOL. Time varying covariates were
selected based on causal diagram analysis of factors that
might affect HZ incidence; CD4+ T cell counts, CD8+ T
cell counts and HIV viral load were potential intermediate
variables, while quality of life score and acyclovir use since
the last study visit were potential confounders.
Statistical analysis
Descriptive statistics such as mean and proportions were
used to assess distributions of background covariates be-
fore and after propensity score matching. Kaplan-Meier
method was used to describe HZ free curves during
study follow up. Cox proportional hazards models were
used to estimate associations of risk factors with time to
first HZ event from the index visit, as reflected by haz-
ard ratios (HR) and their corresponding 95% confidence
intervals (CI). The underlying proportional hazard as-
sumption in the Cox models was assessed for each co-
variate, and we found the assumption was satisfied, with
the smallest P value being 0.2959. Values of time varying
variables at the last study visit were excluded from ana-
lyses to avoid temporal ambiguity. For example, acyclo-
vir use that was reported at the visit at which HZ was
first reported was not counted as acyclovir use prior to
HZ since the drug may have been prescribed to treat
HZ. Univariate associations were first evaluated and only
variables significant in univariate analysis were included
in multivariate models. For short-term HAART effect,
the study was assumed to end one year after the index
visit. For long-term HAART effect, the participants were
followed from the index visits to either their first HZ
event or censored events such as death, loss to follow up
or at the last visit (visit 30). To assess the effect of
HAART use on HZ incidence, we assumed that a wo-
man who initiated HAART will continue on HAART,
which is similar to an intent-to-treatment analysis in a
clinical trial. To assess the effect of HAART adherence
on HZ incidence, time varying HAART adherence level
was used as exposure variable, which is similar to theas-treated analysis in a clinical trial. To examine whe-
ther HAART exerts its effect via immune recovery, we
purposely added into the multivariate models an inter-
mediate variable between HAART use and HZ incidence,
along with an exposure variable and potential confoun-
ders. All statistical analyses were carried out using SAS 9.2
(SAS Inc, Carey, NC).
Results
Trends in HAART use and HZ incidence in the WIHS
2,813 HIV-infected WIHS women were followed from
the WIHS enrollment until visit 30 (2009) and contribu-
ted 22,658 person years. Figure 1 shows trends in HAART
use and HZ incidence among these women during this
period. HZ incidence decreased substantially during the
first few years and it declined steadily thereafter, coinci-
dent with an increase in the proportion of HIV-infected
women taking HAART.
Propensity score matching and participant characteristics
balancing
Characteristics of all HAART using women (2053) and
all HAART naïve women (760) at the WIHS enrollment,
and characteristics of the subsets of these women who
were matched by propensity score at the index visit are
presented in Table 1. At the WIHS enrollment, distribu-
tions of age, race, AIDS diagnosis, HIV viral load, CD4+
and CD8+ cell counts were significantly different be-
tween HAART use and HAART naïve women. However,
after propensity score matching, all background covari-
ates of the 389 matched pairs were well balanced at the
index visit.
Comparison of HZ free curves between the HAART use
group and HAART naïve group
During the follow up, the 389 matched pairs contributed
3,909 person years and reported 109 HZ events. The
HAART use group had a median follow-up time of 6.9
years (interquartile range (IQR: 25th percentile to 75th
percentile): 3.5-11 years) and an average HZ incidence
of 25 (95% confidence interval(CI): 20–32) per 1000
person years. The HAART naïve group had a median
follow-up time of 1.5 years (IQR: 0.7-3.8 years) and an
average HZ incidence of 35 (95% CI: 26–48) per 1000
person years Figure 2 describes the cumulative proba-
bility of remaining HZ free (i.e. not developing HZ) for
the HAART use group and the HAART naïve group.
During the first year of follow up, HZ-free survival was
similar. However, with additional follow-up, the diffe-
rence started showing up. Overall, the HAART naïve
group had marginally lower HZ-free survival (i.e. a
higher incidence of HZ) over time than the HAART
use group (P = 0.113).
Figure 1 Trends in percentage of HAART users and herpes zoster Incidence among HIV-infected women in the WIHS.
Table 1 Characteristics comparison before and after matching










(N = 2053) (N = 760) (N = 389) (N = 389)
Age, mean (SDa) 35 (7.9) 37 (7.6) <.0001 39.7 (8.7) 39.4 (8.2) 0.57
Race, N (%) 0.015 0.81
White, non-hispanic 308 (15.0) 122 (16.1) 57 (14.7) 52 (13.4)
Black, non-hispanic 1119 (54.5) 451 (59.3) 233 (59.9) 246 (63.2)
Hispanic 560 (27.3) 162 (21.3) 88 (22.6) 80 (20.6)
Other 66 (3.2) 25 (3.3) 11 (2.8) 11 (2.8)
Education, N (%) 0.086 0.64
Less than high school 759 (37.1) 304 (40.1) 148 (38.1) 158 (40.6)
Completed high school 612 (29.9) 237 (31.2) 126 (32.4) 127 (32.7)
Some college and above 677 (33.1) 218 (28.7) 115 (29.6) 104 (26.7)
AIDS, N (%) 407 (19.8) 308 (43.08) <.0001 135 (34.7) 138 (35.5) 0.82
CD4+ cell counts, mean (SD) 430 (291.7) 398 (365.3) <.0001 372.6 (248.1) 358.7 (279.2) 0.47
CD8+ cell counts, mean (SD) 899.7 (464.1) 792.2 (597.3) <.0001 847.2 (519.3) 806.8 (521.4) 0.28
log10 (Viral load), mean (SD) 3.9 (1.1) 4.4 (1.2) <.0001 3.9 (1.1) 4.1 (1.2) 0.14
Quality of life score, mean (SD) 64.8 (20.4) 57.4 (21.2) 0.18 63.8 (21.5) 62.4 (22.2) 0.35
astandard deviation; bWIHS: Women’s Interagency HIV Study; cHAART: highly active anti-retroviral therapy.
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Figure 2 Percentage without herpes zoster for HAART treatment and HAART naïve group.
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During the first year of follow up, the HAART use group
and the HAART naïve group reported 13 (incidence
rate: 49 per 1000 person years; 95% CI (29, 82)) and
12 (incidence rate: 47 per 1000 person years, 95% CI
(27, 81)) HZ events respectively. In the univariate ana-
lysis, compared to the HAART naïve group, neither the
HAART use group (HR: 0.88; 95% CI: 0.39-1.99) nor
women with a HAART adherence level of ≥95% (HR:
1.20; 95% CI: 0.42-3.11) had significantly different risk
of HZ incidence.
Long-term Effects of HAART on HZ incidence
Effects of long-term HAART use and HAART adherence
on HZ incidence are described in Table 2. In univariate
analysis, the HAART use group had a marginally lower
HZ incidence (HR: 0.72; 95% CI: 0.48-1.09) compared to
the matched HAART naïve group. However, women
with a HAART adherence level of ≥95% had signifi-
cantly lower HZ incidence (HR: 0.54; 95% CI: 0.31-0.94)
than HAART naïve individuals, while women with lower
HAART adherence levels (less than 95%) or HAART dis-
continuation had similar HZ risk to that of the HAART
naïve group. Higher CD4+ T cell counts (per 100 increase;
HR: 0.85; 95% CI: 0.77-0.93) was significantly associated
with lower HZ incidence while higher HIV viral load
(per log10 increase; HR: 1.55; 95% CI: 1.30-1.84) was
significantly related to higher HZ incidence. After ad-
justing for QOL score and acyclovir use, a HAARTadherence level of ≥95% remained significantly associ-
ated with lower HZ incidence. However, after adding
an intermediate variable - either CD4+ T cell count or
HIV viral load, along with QOL score and acyclovir use,
the association of a HAART adherence level of ≥95% with
HZ incidence attenuated and was no longer statistically
significant.
Discussion
Though the mechanisms by which HAART exerts its ef-
fect on HZ incidence are not yet clear, accumulating evi-
dence suggests that HAART might have different effects
on HZ incidence depending on how long HAART has
been used. Many studies demonstrated that HZ occurs
at a high level shortly after initiation of HAART [4-15],
which might reflect dysregulated immune responses
against pre-existing varicella zoster antigens at the be-
ginning of immune restoration, rather than profound
immunosuppression [4,27]. However, like a few other
observational studies [2,16], we did not observe such a
phenomenon in this study. Possible reasons for this dis-
crepancy might include: (1). HAART users in our study
had higher CD4+ T cell counts (372 cells/μl) before
starting HAART; (2). In this short term analysis, our
study might not have sufficient power to detect minor
difference in HZ incidence due to relatively small sample
size and rarity of HZ events; (3). Participants were
followed every 6 months and the exact dates of HAART
initiation could not be determined.
Table 2 Long-term effect of haarta use on herpes zoster incidence
Variable Univariate Multivariate1 Multivariate2 Multivariate3




HAART use adherence since last visitc
>95% 0.54*(0.31–0.94) 0.56*(0.32–0.99) 0.61(0.33–1.11) 0.76(0.41–1.38)
75%–95% 0.32(0.09–1.05) 0.31(0.09–1.03) 0.30(0.09–1.03) 0.34(0.10–1.14)
0 < adherence <75% 1.70(0.70–4.14) 1.38(0.53–3.63) 1.25(0.46–3.41) 1.23(0.46–3.31)
HAART users, but did not use HAART since last visit 0.95(0.52–1.72) 0.87(0.47–1.62) 0.77(0.39–1.52) 0.65(0.33–1.27)
No HAART users 1.00 1.00 1.00 1.00
Current CD4+ cell counts (per100 cell increase)d 0.85***(0.77–0.93) 0.86***(0.78–0.94)
Current CD8+ cell counts (per 100 cell increase)d 0.96(0.90–1.01)
HIV viral load (per Log 10)d 1.55***(1.30–1.84) 1.59***(1.31–1.93)
Quality of life scored 0.98**(0.97–0.99) 0.99*(0.98–0.99) 0.98*(0.97–0.99) 0.98*(0.97–0.99)
Used acyclovir since last visitd:
No 1.00 1.00 1.00 1.00
Yes 1.88*(1.04–3.18) 1.68(0.88–3.22) 1.52(0.75–3.10) 1.56(0.79–3.08)
aHAART: highly active antiretroviral therapy; bhazard ratio; c95% confident interval; dtime dependent variables ***p < 0.001; **0.001 ≤ p < 0.01; *0.01 ≤ p < 0.05;
1after adjusting for quality of life and acyclovir use; 2after adjusting for quality of life, acyclovir use and CD4+ T cell counts; 3after adjusting for quality of life,
acyclovir use and HIV viral load.
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crease in HZ incidence over time has been observed
among HIV-infected women in the WIHS coincident
with their increasing access to HAART. Like many other
studies [18-21,28], ours showed a protective effect of
long-term HAART use on HZ incidence. However, a sta-
tistically significant effect was achieved only when a
HAART adherence level of ≥95% was attained. Thus, a
further examination of the role of HAART adherence
level might shed light on the lack of associations be-
tween HAART use and HZ incidence as reported by
some earlier studies as no such information was re-
ported [16]. In addition, we found that the long-term ef-
fect of HAART on HZ incidence was mainly mediated
through its effects in reducing HIV viral load and im-
proving host immune status. Enhanced immune status
and decreased shedding of varicella zoster virus antigen
by HAART [29] might explain the protective effect of
HAART on HZ incidence as observed in our study.
In this study, we found that acyclovir use was surpris-
ingly associated with higher HZ incidence in univariate
analysis. Possible explanation for this lies in that prior
acyclovir use might be an indication of other herpes
infections that were closely related to HZ incidence due
to common cause - immunosuppression by HIV infec-
tion, rather than be used to prevent occurrence of HZ
[30,31]. In addition, lower overall QOL was also asso-
ciated with higher incidence of herpes zoster, which isconsistent with the role of psychological stress in the de-
velopment of HZ [32].
Our study had some advantages over previous studies.
First, we used a propensity score matching method to
balance background covariates. In this way, the indi-
cation bias for HAART initiation was dramatically de-
creased. Second, previous studies focused on HAART
use but did not take into account HAART adherence
level. Our study showed the protective effect of HAART
use was most clear when a ≥95% HAART adherence
level was attained, suggesting that HAART adherence
level should always be considered in future similar stu-
dies. However, some limitations of our study should also
be mentioned. First, self-reported HZ was not docu-
mented by a health professional; however, a previous
study has ascribed high validity to self-reports of HZ
[33], suggesting that HZ misclassification in our study
was likely to be very low. Second, we used self-reported
HAART adherence as an exposure variable. However,
this concern might be mitigated by the fact that the rela-
tionships between the WIHS participants and their in-
terviewers have been built on trust and respect over
many years, and previous WIHS research has shown that
self-reported medication use is consistent with objective
measures of HIV outcomes, such as CD4+ T-cell count,
HIV viral load, and self-reported physical functioning
[34]. Lastly, our study only included women, and the re-
sults might not be generalizable to men.
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We have shown that individuals highly adherent to
HAART regimes had a significantly lower incidence of
HZ than similar individuals who were not as adherent to
HAART, underscoring the importance of high HAART
adherence level in the clinical management of HIV-
infected individuals, in addition to its role in decreasing
HIV disease progression and HIV transmission.
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